Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Location: Germany, Saxony, Dresden
Total raised: $12.5M
Investors 1
| Date | Name | Website |
| 19.05.2025 | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.03.2023 | Seed | $12.5M | Forbion |
Mentions in press and media 4
| Date | Title | Description |
| 23.02.2025 | 18th Annual European Life Sciences CEO Forum | The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of Februar... |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 16.03.2023 | Seamless Therapeutics Raises $12.5M in Seed Financing | Seamless Therapeutics, a Dresden, Germany-based biotechnology company providing a recombinase platform, raised $12.5M in Seed funding. The round was led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio. Represe... |
| - | Seamless Therapeutics | “Seamless Therapeutics – Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.” |